INTRODUCTION
Hepatitis B virus (HBV) and Hepatitis C virus infection are leading causes of chronic liver disease worldwide, affecting 350-400million and 170 million people, respectively [1] . HCV is currently the most significant public health problem in Egypt [2] . The recently published Egyptian Demographic and Health Survey (EDHS) in 2015 estimated an overall antibody to hepatitis C virus (anti-HCV) prevalence of 6.3% [3] . Antihepatitis B core (anti-HB C ) seropositivity in general population in Egypt is reported to be 10-13% [4] .
HBV and HCV share common modes of transmission, thus simultaneous infection is quite frequent, particularly where both viruses are endemic as among people with a high risk for parenteral infections [5] . HCV infection has a suppressive effect on the replication of HBV, shown by the loss of replicative markers as HBV-DNA [6] . The extensive application of sensitive molecular tests such as polymerase chain reaction (PCR) and real-time PCR has enabled HBV-DNA to be detected in specimens from individuals without serological evidence of chronic HBV infection [7] .
Occult HBV infection (OBI) can be defined by the presence of HBV-DNA in the serum of patients who are negative for HB S Ag [8] . In the last decade, OBI pattern has been documented and frequently identified in patients with chronic hepatitis C (CHC) infection [9] . The prevalence of OBI in chronic HCV patients was higher in subjects having either antiHBs or anti-HB C Treatment of chronic hepatitis C virus (HCV) infection has been revolutionized in the last few years by the introduction of highly effective and well-tolerated DAAs able to achieve high rates of sustained virological response(SVR) in many groups of patients [11] . In past years, HBV reactivation occurring in HBV/HCV-co-infected patients treated with IFN-based therapy has been reported, probably as a consequence of an unbalanced HBV replication caused by treatmentrelated suppression of HCV, although a direct immune-modulatory effect of IFN might also be advocated for either on-or off-treatment HBV reactivation [12] .
In contrast, DAAs have no effect on HBV replication, but such therapies may release HBV from HCV suppressive effects, resulting in HBV reactivation in CHC patients with a concomitant overt or occult HBV Infection, leading to acute hepatitis with the risk of liver failure both on-or off-treatment This study was performed to determine the prevalence of anti-HBc and frequencies of hepatitis B virus (HBV) DNA and antibodies to hepatitis B surface antigen (anti-HBs) among chronic hepatitis C patients before antiviral therapy.
PATIENTS AND METHODS
Type of Study: Follow up descriptive study.
Site of Study: Port-Said center for treatment of viral hepatitis in Port-Said Fever Hospital.
Study Population:
Chronic hepatitis C patients treated with Sofosbuvir-based regimens.
Criteria of selection:
All 178 patients enrolled in this study were previously diagnosed as chronic hepatitis C patients aged 18-70 years. All patients which had decompensated liver diseases, hepatocellular carcinoma, extra-hepatic malignancy and uncontrolled diabetes mellitus (HbA1c >8%) were excluded. All these criteria were according to the protocol provided by national committee for control of viral hepatitis in Egypt (NCCVH) in December 2016.
Study methods:
Patients who enrolled into the study assessed anti-HB C in serum of CHC patients before starting Direct Acting Anti-viral(DAAs) treatment regimen if positive assess HBV-DNA at baseline, end of treatment and at SVR12weeks. A-Data collected by personal interview included: 
RESULTS
A Total of 178 chronic hepatitis C patients initiated treatment with DAAs. Eighty four patients (47.2%) were treated with difficult treatment (SOF/DAC/RBV) and ninety four patients (52.8%) with easy treatment (SOF/ DAC). one hundred and seventy patients were treated for 12 weeks and eight treated for 24 weeks (Table 1 ). There were no significant differences between chronic hepatitis C patients with positive HBcAb vs. those with negative HBcAb regarding sex, age, history of smoking, Hemoglobin, and HCV RNA. However, positive HBcAb patients had significantly diabetes mellitus (Table 2 ). There was no significant correlation between liver enzymes and HBcAb seropositivity. However ALT and AST had reasonable sensitivity around 70% at cut off points 29.5 and 32.5 respectively the specificity dropped to25.4%and 40.4%, respectively ( Figure 1 ). 
DISCUSSION
In this study OBI seroprevalence tested by HBcIgG Elisa has positive for sixty four patients(35%)with mean age of 54.6years old ,more in males (53.1%) than females (46.9%), type 2 diabetes mellitus (18.5%), highly Fib 4 index >3.25 and highly HCVRNA(5.8x10 5 IU/ml). The EDHS 2015 included tests for anti-hepatitis B core antibody (anti-HB) and hepatitis B surface antigen (HBsAg) in addition to testing for HCV. The age prevalence of anti-HBc (indicating exposure to hepatitis B virus [HBV] infection) mirrors the age prevalence of anti-HCV in both males and females.
The incidence of OBI in HCV patients varies greatly, ranging from 0% to 52% [15] . In this study; 35% of HCV patients were sero-positive for OBI. Our results were in agreement with those reported among Mediterranean countries [16] . . Also, Emara et al. [15] reported that this seemed to be applicable to genotype 4, where HBV-DNA positive patients in their study showed higher baseline HCV viral load than HCV mono-infected patients.
Also, Chen et al. [19] reported that patients with both OBI and HCV infection had lower ALT However, further prospective studies in large cohorts of OBI patients better characterized from the virological point of view at baseline and during and after EOT are needed to quantify and stratify the risk of HBV reactivation in parallel with HCV eradication, and to standardize the management of such patients in order to avoid the risk of fatal complication.
CONCLUSION
In conclusion, occult hepatitis B Infection is highly prevalent in chronic hepatitis C infection and not depend on HBs Ag only in diagnosis for HBV infection. In future we need to check for HBsAg, anti HBc, and if positive screen for HBVDNA PCR in chronic hepatitis C infection treated with oral direct acting antiviral drug in initial visit, end of treatment and after 12 weeks of treatment for fear of reactivation of HBV infection.
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